文献速递免疫规划妇幼与学校卫生

孕期或孕前接种COVID-19疫苗与妊娠期高血压疾病风险

COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.
PubMed 文献 · Vaccine · 2026-02-02

本研究采用匹配队列设计,比较CDC COVID-19疫苗妊娠登记(C19VPR)与妊娠风险评估监测系统(PRAMS)中无产史单胎活产孕妇,发现接种组自报妊娠期高血压疾病(HDP)的调整相对风险为1.24(95%CI 1.08-1.43),且孕期报告COVID-19疾病者HDP风险为1.28(95%CI 1.02-1.60)。作者指出两组来自不同队列,关联不能视为因果。

要点

  • 接种组自报HDP风险较未接种组升高,调整RR=1.24(95%CI 1.08-1.43)。
  • 孕期报告COVID-19疾病者HDP风险调整RR=1.28(95%CI 1.02-1.60)。
  • 两组来自不同队列,观察到的关联不能视为因果。

核心结论

  • 接种COVID-19疫苗的孕妇自报HDP风险高于未接种者,但两组来自不同队列。
  • 孕期报告COVID-19疾病者的HDP风险与接种者相似。
  • 因队列差异,观察到的关联不能视为因果,需更新评估。

研究设计与样本

  • 匹配队列研究,数据来自CDC COVID-19疫苗妊娠登记(C19VPR,接种组)和妊娠风险评估监测系统(PRAMS,未接种组)。
  • 按年龄组、种族/民族和分娩时孕周匹配。
  • C19VPR符合条件的8030人中8024人(99.9%)匹配到PRAMS参与者。

主要发现

  • C19VPR参与者98.9%在2021年分娩;PRAMS参与者54.5%在2020年、17.4%在2019年分娩。
  • 接种组 vs 未接种组自报HDP的调整RR=1.24(95%CI 1.08-1.43)。
  • 未观察到疫苗制造商或接种时机(<20周或≥20周)的效应修饰。
  • 限制在2021年分娩的匹配对(n=2231)分析结果相似。
  • 有孕期COVID-19疾病数据的匹配对(n=4039)中,报告疾病者 vs 未报告者HDP调整RR=1.28(95%CI 1.02-1.60)。

临床怎么用

  • 为孕妇接种COVID-19疫苗时,应告知其自报HDP风险升高的观察性信号。
  • 孕期COVID-19疾病本身也与HDP风险升高相关,支持孕期免疫接种的获益-风险评估。
  • 鉴于非因果性,不宜据此改变临床实践,应结合个体情况并关注后续更新证据。

局限性

  • 接种组与未接种组来自不同队列(C19VPR vs PRAMS),存在队列差异。
  • HDP和COVID-19疾病均为自报结局。
  • 观察到的关联不能视为因果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertensive disorders of pregnancy (HDP) are leading causes of maternal and fetal morbidity/mortality. To identify potential safety concerns, we evaluated whether COVID-19 vaccination during pregnancy or within 30 days of last menstrual period was associated with self-reported HDP. We also evaluated HDP risk associated with COVID-19 illness during pregnancy. We conducted a matched cohort study using data from the Centers for Disease Control and Prevention's COVID-19 Vaccine Pregnancy Registry (C19VPR; vaccinated) and Pregnancy Risk Assessment Monitoring System (PRAMS; unvaccinated). Participants included nulliparous women with singleton pregnancies ending in livebirth (C19VPR, December 2020-March 2022; PRAMS, 2019-2021). Participants were matched by age group, race/ethnicity, and gestational age at delivery. We estimated relative risk (RR) for self-reported HDP by vaccination status using Poisson regression, adjusting for confounders. We tested for effect modification by vaccine manufacturer and vaccination timing (<20 or ≥ 20 weeks' gestation). Among matched pairs with data on self-reported COVID-19 illness in pregnancy, we estimated risk of HDP by illness status. Of 8030 eligible C19VPR participants, 8024 (99.9%) were matched to a PRAMS participant. Most C19VPR participants delivered in 2021 (98.9%); PRAMS participants delivered predominantly in 2020 (54.5%) and 2019 (17.4%). Adjusted RR for HDP was 1.24 (95% confidence interval [CI]: 1.08, 1.43) among C19VPR versus PRAMS participants. We observed no effect modification. Results of an analysis restricted to matched pairs who delivered in 2021 (n = 2231) were similar. Among matched pairs (n = 4039) with data on COVID-19 illness in pregnancy, adjusted RR for HDP was 1.28 (95%CI: 1.02, 1.60) for those reporting illness compared with no illness. Risk of HDP was higher among COVID-19 vaccinated compared to unvaccinated women; however, the two groups were sampled from different cohorts. Risk was similar to those who reported COVID-19 illness. Given cohort differences, the associations observed cannot be considered causal; updated assessments of HDP risks after illness and vaccination would be useful.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sharma AJ, Smoots AN, Madni SA, et al. COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy. Vaccine. 2026. PMID: 41633278. doi:10.1016/j.vaccine.2026.128268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。